New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1

Journal of Medicinal Chemistry

Volumn 56, Issue 5, 2013, Pages 2029-2037

  Dang, Zhao ^a   Ho, Phong ^a   Zhu, Lei ^a   Qian, Keduo ^b   Lee, Kuo Hsiung ^b,c   Huang, Li ^a   Chen, Chin Ho ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (BOC AMINO) 4 CYANO N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 8 AMINOOCTYL]BUTANAMIDE; BENZYL N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONANOYL] LEVO GLUTAMINATE; BEVIRIMAT; DIMETHYL N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONANOYL] LEVO GLUTAMATE; METHYL N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 10 AMINODECANOYL] LEVO GLUTAMINATE; METHYL N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 7 AMINOHEPTANOYL] LEVO GLUTAMINATE; METHYL N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 7 AMINONONANOYL] LEVO GLUTAMINATE; METHYL N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 8 AMINOOCTANOYL] LEVO GLUTAMINATE; METHYL N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONANOYL] LEVO ALANINATE; METHYL N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONANOYL] LEVO GLYCINATE; METHYL N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONANOYL] LEVO ISOLEUCINATE; METHYL N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONANOYL] LEVO PHENYLALANINATE; METHYL N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONANOYL] LEVO PROLINATE; METHYL N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONANOYL] LEVO VALINATE; N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 7 AMINOHEPTYL] NA BOC LEVO ALANINAMIDE; N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 7 AMINOHEPTYL] NA BOC LEVO GLUTAMINAMIDE; N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 8 AMINOOCTYL] NA BOC LEVO ALANINAMIDE; N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 8 AMINOOCTYL] NA BOC LEVO GLUTAMINAMIDE; N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 8 AMINOOCTYL] NA BOC LEVO PROLINAMIDE; N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 8 AMINOOCTYL] NA BOC LEVO VALINAMIDE; N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONACTYL] NA BO LEVO ALANINAMIDE; N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONACTYL] NA BOC LEVO ASPARAGINAMIDE; N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONACTYL] NA BOC LEVO GLUTAMINAMIDE; N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONACTYL] NA BOC LEVO GLYCINAMIDE; N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONANOYL] AMINOACETONITRILE; N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONANOYL] AMINOPROPIONITRILE; N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONANOYL] LEVO GLYCINE; N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONANOYL] N METHYL AMINOACETONITRILE; T BUTYL N [N' [3BETA O (3',3' DIMETHYLSUCCINYL) BETULINIC ACID 28 OYL] 9 AMINONONANOYL] LEVO GLUTAMINATE; TERPENOID DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SENSITIVITY; DRUG SYNTHESIS; GENETIC POLYMORPHISM; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; VIRUS STRAIN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS; POLYMORPHISM, GENETIC; SUCCINATES; TRITERPENES; VIRUS REPLICATION;

EID: 84875202040     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3016969     Document Type: Article

References (26)

1. De Cock, K. M.; Jaffe, H. W.; Curran, J. W. The evolving epidemiology of HIV/AIDS AIDS 2012, 26, 1205-1213
2. Chun, T. W.; Carruth, L.; Finzi, D.; Shen, X.; DiGiuseppe, J. A.; Taylor, H.; Hermankova, M.; Chadwick, K.; Margolick, J.; Quinn, T. C.; Kuo, Y. H.; Brookmeyer, R.; Zeiger, M. A.; Barditch-Crovo, P.; Siliciano, R. F. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection Nature 1997, 387, 183-188 (Pubitemid 27209433)
3. Wong, J. K.; Hezareh, M.; Günthard, H. F.; Havlir, D. V.; Ignacio, C. C.; Spina, C. A.; Richman, D. D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia Science 1997, 278, 1291-1295 (Pubitemid 27495741)
4. Finzi, D.; Hermankova, M.; Pierson, T.; Carruth, L. M.; Buck, C.; Chaisson, R. E.; Quinn, T. C.; Chadwick, K.; Margolick, J.; Brookmeyer, R.; Gallant, J.; Markowitz, M.; Ho, D. D.; Richman, D. D.; Siliciano, R. F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Science 1997, 278, 1295-1300 (Pubitemid 27495742)
5. Lataillade, M.; Chiarella, J.; Yang, R.; Schnittman, S.; Wirtz, V.; Uy, J.; Seekins, D.; Krystal, M.; Mancini, M.; McGrath, D.; Simen, B.; Egholm, M.; Kozal, M. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study PLoS One 2010, 5, e10952
6. Jakobsen, M. E.; Jakobsen, M. R; Tolstrup, M.; Søgaard, O. S.; Jørgensen, L. B.; Gorry, P. R.; Laursen, A.; Ostergaard, L. Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome Clin. Infect. Dis. 2010, 50, 566-573
7. Aiken, C.; Chen, C. H. Betulinic acid derivatives as HIV-1 antivirals Trend Mol. Med. 2005, 11, 31-36 (Pubitemid 40092672)
8. Kashiwada, Y.; Hashimoto, F.; Cosentino, L. M.; Chen, C. H.; Garrett, P. E.; Lee, K. H. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents J. Med. Chem. 1996, 39, 1016-1017 (Pubitemid 26082932)
9. Li, F.; Goila-Gaur, R.; Salzwedel, K.; Kilgore, N. R.; Reddick, M.; Matallana, C.; Castillo, A.; Zoumplis, D.; Martin, D. E.; Orenstein, J. M.; Allaway, G. P.; Freed, E. O.; Wild, C. T. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 13555-13560 (Pubitemid 37444780)
10. Zhou, J.; Yuan, X.; Dismuke, D.; Forshey, B. M.; Lundquist, C.; Lee, K. H.; Aiken, C.; Chen, C. H. Pharmacologic inhibition of HIV-1 replication by a novel mechanism: specific interference with the final step of virion maturation J. Virol. 2004, 78, 922-929 (Pubitemid 38067613)
11. Smith, P. F.; Ogundele, A.; Forrest, A.; Wilton, J.; Salzwedel, K.; Doto, J.; Allaway, G. P.; Martin, D. E. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3- o -(3′,3′-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection Antimicrob. Agents Chemother. 2007, 51, 3574-3581 (Pubitemid 47519346)
12. Martin, D. E.; Blum, R.; Doto, J.; Galbraith, H.; Ballow, C. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers Clin. Pharmacokinet. 2007, 46, 589-598 (Pubitemid 47025359)
13. Adamson, C. S.; Sakalian, M.; Salzwedel, K.; Freed, E. O. Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV-1 maturation inhibitor bevirimat Retrovirology 2010, 7, 36
14. Van Baelen, K.; Salzwedel, K.; Rondelez, E.; Van Eygen, V.; De Vos, S.; Verheyen, A.; Steegen, K.; Verlinden, Y.; Allaway, G. P.; Stuyver, L. J. Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1 Antimicrob. Agents Chemother. 2009, 53, 2185-2188
15. McCallister, S.; Lalezari, J.; Richmond, G.; Thompson, M.; Harrigan, R.; Martin, D.; Salzwedel, K.; Allaway, G. HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457) Antivir. Ther. 2008, 13, A10
16. Margot, N. A.; Gibbs, C. S.; Miller, M. D. Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat Antimicrob. Agents Chemother. 2010, 54, 2345-2353
17. Lu, W.; Salzwedel, K.; Wang, D.; Chakravarty, S.; Freed, E. O.; Wild, C. T.; Li, F. A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat Antimicrob. Agents Chemother. 2011, 55, 3324-3329
18. Zhou, J.; Huang, L.; Hachey, D. L.; Chen, C. H.; Aiken, C. Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles J. Biol. Chem. 2005, 280, 42149-42155 (Pubitemid 43023184)
19. Nguyen, A. T.; Feasley, C. L.; Jackson, K. W.; Nitz, T. J.; Salzwedel, K.; Air, G. M.; Sakalian, M. The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles Retrovirology 2011, 8, 101
20. Qian, K.; Bori, I. D.; Chen, C. H.; Huang, L.; Lee, K. H. Anti-AIDS Agents 90. Novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors J. Med. Chem. 2012, 55, 8128-8136
21. Dang, Z.; Lai, W.; Qian, K.; Ho, P.; Lee, K. H.; Chen, C. H.; Huang, L. Betulinic acid derivatives as human Immunodeficiency virus type 2 (HIV-2) inhibitors J. Med. Chem. 2009, 52, 7887-7891
22. Sun, I.; Chen, C. H; Kashiwada, Y.; Wu, J.H.; Wang, H.K.; Lee, K. H. Anti-AIDS agents 49. Synthesis, anti-HIV, and anti-fusion activities of IC9564 analogues based on betulinic acid J. Med. Chem. 2002, 45, 4271-4275 (Pubitemid 35025574)
23. Dang, Z.; Qian, K.; Ho, P.; Zhu, L.; Lee, K. H.; Huang, L.; Chen, C. H. Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants Bioorg. Med. Chem. Lett. 2012, 22, 5190-5194
24. Lai, W.; Huang, L.; Ho, P.; Li, Z. J.; Montefiori, D.; Chen, C. H. Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of HIV-1 Antimicrob. Agents Chemother. 2008, 52, 128-136
25. Mayaux, J. F.; Bousseau, A.; Pauwels, R.; Huet, T.; Hénin, Y.; Dereu, N.; Evers, M.; Soler, F.; Poujade, C.; De Clercq, E. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 3564-3568 (Pubitemid 24139470)
26. Holz-Smith, S. L.; Sun, I. C.; Jin, L.; Matthews, T. J.; Lee, K. H.; Chen, C. H. Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564 Antimicrob. Agents Chemother. 2001, 45, 60-66 (Pubitemid 32039094)